Treatment of Opioid Use Disorder: Waiver Qualifying - Johns Hopkins Nursing - Saturday, September 22, 2018

  • Registration Closed. Maximum Number of Registrants reached.

image

Saturday, September 22, 2018 | 8:00 am - 5:30 pm

Johns Hopkins School of Nursing
Pinkard Building, Room 217
525 N. Wolfe Street
Baltimore, MD 21205

Cost: FREE

Hosted by: 
Johns Hopkins School of Nursing


Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physicians, nurse practitioners, and physicians assistants who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office ‐ based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

For NPs (CE Credit through AANP): Click Here
 
For PAs (AAPA Category 1 CME Credit): Click Here


Click here to view additional resources.

Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

CME Information and Disclosure Listing

Date of Release: July 2015
Approved Through: December 2019

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Dan Alford, MD, MPH, DFASAM, Chair

None

Paula J. Lum, MD, MPH, FASAM, Vice Chair

None

Edwin Salsitz, MD, DFASAM, Curriculum Director

None

Soraya Azari, MD

None 

Jill Mattingly, DHSc, MMSc, PA-C

None

Debra Newman, PA-C, MPAS, MPH

None

Mary McMasters, MD, DFASAMNone

Yngvild K. Olsen, MD, MPH, DFASAM

None
Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
Kristin Smith, DNP, FNP-C, AAHIVSNone
Tricia E. Wright, MD, MS, FACOG, FASAMNone

ASAM CME Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Catherine Friedman, MD, FAPA, DFASAM, Chair

None

R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
Adam J. Gordon, MD, MPH, FACP, DFASAMNone
Zwaantje Hamming, FNP-C, CARN-APNone

Herbert L. Malinoff, MD, FACP, DFASAM

None

Noel Ilogu, MD, MRCP, DFASAM

None

Edwin A. Salsitz, MD, DFASAM

None

ASAM Staff and Consultants

Arlene C. Deverman, MA, CAE, CFRENone

Marcia Jackson, PhD

None
Sandy MetcalfeNone

ASAM Medical Education Council

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
Daniel P. Alford, MD, MPH, DFASAMNone
Michael Fingerhood, MD, FACP, FASAMNone
Catherine R. Friedman, MD, FAPA, DFASAMNone
Adam J. Gordon, MD, MPH, FACP, DFASAMNone
Miriam S. Komaromy, MD, FACP, DFASAMNone
Edwin A. Salsitz, MD, DFASAMNone
Mark P. Schwartz, MD, DFASAMNone
Mark A. Weiner, MD, FASAMNone
ASAM Staff and Consultants
Penny S. Mills, MBANone
Arlene C. Deverman, MA, CAE, CFRENone
Marcia Jackson, PhDNone
Dawn C. HowellNone
Molly S. MazukNone
Alexandra (Alli) UngerNone
Jennifer L. ButchartNone
ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

At the conclusion of this activity, learners should be able to:

  1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
  2. Identify and assess patients who are appropriate for treatment with medications
  3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
  4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

Licensed physicians, nurse practitioners, and physician assistants who wish to treat patients with opioid use disorder and to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.



  1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

    1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

  2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

  3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

  4. Choose the type of credit (Physician or Non-physician) and click submit

  5. Click the button “View/Print Certificate” to save or print your certificate
    1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


Click here for more information on applying for a waiver to prescribe buprenorphine.

Apply

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
  • Complete no less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Key:

Complete
Failed
Available
Locked
Live In-Person Event
09/22/2018 at 8:00 AM (EDT)   |  1 day, 9 hours, 30 minutes
09/22/2018 at 8:00 AM (EDT)   |  1 day, 9 hours, 30 minutes Attend the live course on September 22, 2018.
The ASAM Treatment of Opioid Use Disorder Course Live Portion CME Evaluation
17 Questions
17 Questions Complete the evaluation to earn CME credit.
CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available 8 Credits